150 related articles for article (PubMed ID: 1825438)
1. Platelet activating factor (PAF) antagonists: development of a highly potent PAF antagonist, TCV-309.
Takatani M; Maezaki N; Imura Y; Terashita Z; Nishikawa K; Tsushima S
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():943-6. PubMed ID: 1825438
[No Abstract] [Full Text] [Related]
2. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of TCV-309--a potent PAF antagonist.
Terashita Z; Takatani M; Nishikawa K
J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598
[TBL] [Abstract][Full Text] [Related]
4. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees.
Kuipers B; van der Poll T; Levi M; van Deventer SJ; ten Cate H; Imai Y; Hack CE; ten Cate JW
J Immunol; 1994 Mar; 152(5):2438-46. PubMed ID: 8133055
[TBL] [Abstract][Full Text] [Related]
5. Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury.
Yin M; Kurvers HA; Buurman WA; Tangelder GJ; Booster MH; Daemen JH; Kondracki S; Kootstra G
Transplant Proc; 1995 Feb; 27(1):774-6. PubMed ID: 7879180
[No Abstract] [Full Text] [Related]
6. Donor administration of PAF antagonist (TCV-309) enhances lung preservation.
Ide S; Kawahara K; Takahashi T; Sasaki N; Shingu H; Nagayasu T; Yamamoto S; Tagawa T; Tomita M
Transplant Proc; 1995 Feb; 27(1):570-3. PubMed ID: 7879103
[No Abstract] [Full Text] [Related]
7. Platelet activating factor (PAF) inhibitor (TCV-309) reduces caerulein- and PAF-induced pancreatitis. A morphologic and functional study in the rat.
Tomaszewska R; Dembiński A; Warzecha Z; Banaś M; Konturek SJ; Stachura J
J Physiol Pharmacol; 1992 Dec; 43(4):345-52. PubMed ID: 1294265
[TBL] [Abstract][Full Text] [Related]
8. Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury.
Yin M; Kurvers HA; Buurman WA; Tangelder GJ; Tiebosch AT; Daemen JH; Kootstra G
Transplant Proc; 1995 Oct; 27(5):2844-6. PubMed ID: 7482939
[No Abstract] [Full Text] [Related]
9. Role of platelet activating factor in cardiac dysfunction, apoptosis and nitric oxide synthase mRNA expression in the ischemic-reperfused rabbit heart.
Loucks EB; Godin DV; Walley KR; McManus BM; Rahimian R; Granville DJ; Hong JM; Aktary FM; Qayumi AK
Can J Cardiol; 2003 Mar; 19(3):267-74. PubMed ID: 12677282
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation.
Kawamura M; Terashita Z; Imura Y; Shino A; Nishikawa K
Thromb Res; 1993 May; 70(4):281-93. PubMed ID: 8332959
[TBL] [Abstract][Full Text] [Related]
11. Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs.
Kawamura M; Kitayoshi T; Terashita Z; Fujiwara S; Takatani M; Nishikawa K
J Lipid Mediat Cell Signal; 1994 May; 9(3):255-65. PubMed ID: 7921785
[TBL] [Abstract][Full Text] [Related]
12. The effects of platelet activating factor antagonist, TCV309, on the relationship between electrophysiological and mechanical status during myocardial ischemia and reperfusion.
Tamura K; Kimura Y; Tamura T; Kitashiro S; Izuoka T; Iwasaka T; Inada M
Ann N Y Acad Sci; 1994 Jun; 723():371-4. PubMed ID: 8030887
[No Abstract] [Full Text] [Related]
13. Platelet-activating factor as a vasodepressive mediator of liver ischemia.
Fukuoka T; Nakajima Y; Nakano H
Transplant Proc; 1993 Dec; 25(6):3225-7. PubMed ID: 8266523
[No Abstract] [Full Text] [Related]
14. Role of platelet activating factor in development of thrombocytopenia and neutropenia in dogs with endotoxemia.
Tsuchiya R; Kyotani K; Scott MA; Nishizono K; Ashida Y; Mochizuki T; Kitao S; Yamada T; Kobayashi K
Am J Vet Res; 1999 Feb; 60(2):216-21. PubMed ID: 10048555
[TBL] [Abstract][Full Text] [Related]
15. Effects of a platelet activating factor antagonist on oedema formation following burns.
Ono I; Gunji H; Hasegawa T; Harada H; Kaneko F; Matsuzaki M
Burns; 1993 Jun; 19(3):202-7. PubMed ID: 8507364
[TBL] [Abstract][Full Text] [Related]
16. An antagonist of platelet-activating factor suppresses endotoxin-induced tumor necrosis factor and mortality in mice pretreated with carrageenan.
Ogata M; Matsumoto T; Koga K; Takenaka I; Kamochi M; Sata T; Yoshida S; Shigematsu A
Infect Immun; 1993 Feb; 61(2):699-704. PubMed ID: 8423096
[TBL] [Abstract][Full Text] [Related]
17. Analogues of platelet activating factor. 8. Antagonists of PAF containing an aromatic ring linked to a pyridinium ring.
Trova MP; Wissner A; Carroll ML; Kerwar SS; Pickett WC; Schaub RE; Torley LW; Kohler CA
J Med Chem; 1993 Mar; 36(5):580-90. PubMed ID: 8496938
[TBL] [Abstract][Full Text] [Related]
18. Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock.
Okano S; Tagawa M; Urakawa N
J Vet Med Sci; 1995 Aug; 57(4):751-3. PubMed ID: 8519912
[TBL] [Abstract][Full Text] [Related]
19. Extended lung preservation with platelet-activating factor-antagonist TCV-309 in combination with prostaglandin E1.
Qayumi AK; English JE; Duncan S; Ansley DM; Pearson B; Nikbakht-Sangari M; Sammartino C; Fradet G
J Heart Lung Transplant; 1997 Sep; 16(9):946-55. PubMed ID: 9322146
[TBL] [Abstract][Full Text] [Related]
20. [PAF-antagonists with a phospholipid structure. 1. Phospholipids with hetero-arene head groups: synthesis, characterization and determination of the action of structural elements].
Kertscher HP; Ostermann G; Findeisen M; Limmer S; Gawrisch K
Pharmazie; 1991 Aug; 46(8):575-9. PubMed ID: 1798710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
